The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2019 | Overcoming carfilzomib resistance
David Simpson, MBChB, FRACP, FRCPA of North Shore Hospital, Auckland, New Zealand, explains the resistance mechanism of myeloma cells to carfilzomib, and describes the success of infusion with ritonavir in patients who have reduced response. Dr Simpson goes on to outline the need to assess the most efficient time for the administration of carfilzomib in myeloma patients in order to eliminate resistance-related cells. This interview was filmed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
